Continued Treatment with Nivolumab May Improve Survival in Patients with Advanced Kidney Cancer
Roswell Park Comprehensive Cancer CenterOnly 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit. The research was published online ahead of print in JAMA Oncology, a journal of the American Medical Association.